# ANTHELCIDE EQ- oxibendazole paste Zoetis Inc.

-----

ANTHELCIDE<sup>®</sup> EQ (oxibendazole) paste

HORSE DEWORMER

For use in horses only

#### DESCRIPTION

Anthelcide EQ Paste is a paste formulation of oxibendazole, a broad-spectrum benzimidazole anthelmintic. This formulation has been developed for ease of administration. Each syringe contains 0.85 oz (24 g) of paste.

Anthelcide EQ Paste contains:
Oxibendazole 22.7%

#### **INDICATIONS**

Anthelcide EQ Paste is indicated for removal and control of: large strongyles (*Strongylus edentatus*, *S. equinus*, *S. vulgaris*); small strongyles (species of the genera *Cylicostephanus*, *Cylicocyclus*, *Cyathostomum*, *Triodontophorus*, *Cylicodontophorus*, and *Gyalocephalus*); large roundworms (*Parascaris equorum*); pinworms (*Oxyuris equi*) including various larval stages; and threadworms (*Strongyloides westeri*).

### **CONTRAINDICATIONS**

Anthelcide EQ is contraindicated in severely debilitated horses or horses suffering from infectious disease, toxemia, or colic.

## Warning

Do not use in horses intended for human consumption.

#### **PRECAUTIONS**

Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.

Keep Out of Reach of Children.

#### OTHER WARNINGS

Parasite resistance may develop to any dewormer, and has been reported for most classes of dewormers. Treatment with a dewormer used in conjunction with parasite management practices appropriate to the geographic area and the animal(s) to be treated may slow the development of parasite resistance. Fecal examinations or other diagnostic tests and parasite management history should be used to determine if the product is appropriate for the herd prior to the use of any dewormer. Following the use of any dewormer, effectiveness of treatment should be monitored (for example, with the use of a fecal egg count reduction test or another appropriate method). A decrease in a drug's effectiveness over time as calculated by fecal egg count reduction tests may indicate the development of resistance to

the dewormer administered. Your parasite management plan should be adjusted accordingly based on regular monitoring.

## DOSAGE AND ADMINISTRATION

The dosage of oxibendazole is 10 mg/kg (2.2 lb) of body weight (15 mg/kg for strongyloides). Each mark on the syringe delivers Anthelcide EQ to treat 100 lb (67 lb for strongyloides). Horses maintained on premises where reinfection is likely to occur should be retreated in 6–8 weeks.

**Do not underdose.** Ensure each animal receives a complete dose based on a current body weight. Underdosing may result in ineffective treatment, and encourage the development of parasite resistance.

**Dosage Table** 

10 mg/kg		15 mg/kg	
Syringe Mark F	Horse Weight (lb	) Syringe Mark H	Iorse Weight (lb)
100	100	300	200
200	200	600	400
400	400	900	600
600	600	1200	800
800	800		
1000	1000		
1200	1200		

Anthelcide EQ is compatible with carbon disulfide, which can be used concurrently for bot control (*Gasterophilus* spp.) when administered by a veterinarian. Routine carbon disulfide cautions must be observed.

#### USE OF SYRINGE

Determine the weight of the horse and dial the correct setting on the plunger, having the side of the wheel nearest the barrel on the desired mark. Remove the cap from the syringe. Insert the tip of the syringe into the side of the animal's mouth between the incisor and molar teeth and press the plunger down as far as it will go, depositing the paste on the back of the tongue.

## **HOW SUPPLIED**

Anthelcide EQ paste is supplied in 0.85-oz (24-g) syringes.

## **STORAGE**

Store at controlled room temperature 15°–30°C (59°–86°F).

Approved by FDA under NADA # 121-042

zoetis

Distributed by: Zoetis Inc. Kalamazoo, MI 49007

40028048

Revised: June 2019

## PRINCIPAL DISPLAY PANEL - 24 g Syringe Label



## ANTHELCIDE EQ

oxibendazole paste

Product	Inform	ation
Promin	ımınrın	allon

Product Type	OTC ANIMAL DRUG	Item Code (Source)	NDC:54771-6045
--------------	-----------------	--------------------	----------------

Route of Administration ORAL

#### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
OXIBENDAZOLE (UNII: 022N12KJ0X) (OXIBENDAZOLE - UNII:022N12KJ0X)	OXIBENDAZOLE	227 mg in 1 g

Pac!	

# Item Code	Package Description	Marketing Start Date	Marketing End Date
1 NDC:54771-6045-2	24 g in 1 SYRINGE		

<b>Marketing</b>	Information
------------------	-------------

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date

NADA NADA121042 10/16/1981

## **Labeler -** Zoetis Inc. (828851555)

Revised: 3/2020 Zoetis Inc.